Latest Us Manufacturing News

Vitrafy Life Sciences reported a breakthrough 94.4% post-thaw platelet recovery in US Army Phase II testing, secured major US blood network partnerships, and raised $32 million to accelerate US expansion and device manufacturing.

LTR Pharma’s SPONTAN shows rapid absorption in Phase II interim data while securing key US commercial deals for ROXUS, setting the stage for a US market entry later this year.

AML3D Limited closed FY26 with a record $29 million order book, driven by US defence contracts and a $12 million investment to double its Ohio manufacturing capacity. The company’s cash receipts rose 20% to $10.4 million, while its sales pipeline expanded to $78 million.

LTR Pharma has locked in a comprehensive commercial agreement with Strive Pharmacy, cementing its manufacturing and fulfilment infrastructure for the upcoming US launch of ROXUS®.

Boresight Ltd has secured a lease for a new 812 square metre manufacturing hub in Huntsville, Alabama, vastly expanding its US production capacity for aerial target drones amid rising military demand.

AML3D has completed its initial $4.5 million delivery of two ARCEMY® X systems to Newport News Shipbuilding, the largest US military shipbuilder, with a follow-up order worth $9.9 million underway for early 2027 delivery.

Fluence Corporation has landed a $3.7 million contract to build a high-capacity water treatment plant in Texas, aiming to reduce industrial reliance on municipal water amid ongoing drought conditions.

AML3D has installed its first portable ARCEMY additive manufacturing system at the US Navy's Additive Manufacturing Centre of Excellence, marking a milestone in its partnership with Austal USA and expanding its footprint in military-grade 3D printing.

Volt Resources is making headway in securing US customers for its Alabama Graphite Refinery, leveraging recent policy shifts and supply chain dynamics to target near-term revenue from industrial and battery markets.

Clarity Pharmaceuticals’ Phase II Co-PSMA trial confirms its Cu-SAR-bisPSMA PET imaging detects more than twice the prostate cancer lesions versus standard care, driving patient management changes. Phase III AMPLIFY recruitment closes, manufacturing deals inked, and cash sits near $198 million.

Botanix Pharmaceuticals reported a 5% rise in Sofdra prescriptions in Q3 FY26 despite a dip in net revenue due to insurance deductible resets, strengthened by a $45 million capital raise and a new API supply deal with Piramal.

IDT Australia is poised for its strongest FY26 finish since its transformation began, forecasting a dramatic narrowing of EBITDA losses and revenue growth driven by strategic partnerships and operational upgrades.